Get started
Work

Trends in Buprenorphine Coverage and Prior Authorization Requirements in US Commercial Formularies, 2017-2021

Year: 2022
Type: article
Abstract: Extended-release buprenorphine injection Immediate-release buprenorphineA, Coverage of buprenorphine products in commercial formularies; B, Prior authorization requirements for buprenorphine products in commercial formularies.Data were derived from 866 commercial formularies included in the Ideon database throughout 2017 to 2021.The bars represent the 95% CIs for the proportions.The denominators for the proportions in Panel B are the numbers of formularies that covered at least 1 immediate-release buprenorphine product and the number that covered extended-release buprenorphine injection (Sublocade).
DOI: 10.1001/jamahealthforum.2022.1821
Institutions: University of Michigan, Michigan Medicine, University of Central Florida, University of Georgia, National Bureau of Economic Research, Indiana University Bloomington, Indiana University
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $5,000
Funders: Robert Wood Johnson Foundation, Arizona State University, Health Foundation of South Florida, Ministry of Urban Development, National Institutes of Health, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, National Institute on Drug Abuse, Janssen Pharmaceuticals
OpenAlex ID: W4284965484
FWCI: 1.479
Cites: 6
Cited by: 8
Related to: 10